Secondary prevention of hyperkalemia with sodium polystyrene sulfonate in cardiac and kidney patients on renin-angiotensin-aldosterone system inhibition therapy

Clinical Cardiology

Volumn 35, Issue 1, 2012, Pages 32-36

  Chernin, Gil ^a   Gal Oz, Amir ^a   Ben Assa, Eyal ^a   Schwartz, Idit F ^a   Weinstein, Talia ^a   Schwartz, Doron ^a   Silverberg, Donald S ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM; CANDESARTAN; ENALAPRIL; HEMOGLOBIN; IRON; LOOP DIURETIC AGENT; LOSARTAN; PHOSPHORUS; POLYSTYRENESULFONATE SODIUM; POTASSIUM; RAMIPRIL; SODIUM; SPIRONOLACTONE; VALSARTAN;

ACUTE CHOLECYSTITIS; ACUTE HEART INFARCTION; ADULT; AGED; ANEMIA; ASYMPTOMATIC DISEASE; CHOLANGITIS; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; COLON DISEASE; DRUG DOSE REDUCTION; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEART DISEASE; HEART LEFT VENTRICLE FAILURE; HEMODIALYSIS; HOSPITALIZATION; HUMAN; HYPERKALEMIA; HYPOKALEMIA; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; LUNG EDEMA; MALE; MEDICAL RECORD REVIEW; NECROSIS; PHARMACOLOGICAL BLOCKING; POTASSIUM BLOOD LEVEL; RECURRENT DISEASE; RECURRENT INFECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM INHIBITION THERAPY; REVIEW; SECONDARY PREVENTION; SEPSIS; SIDE EFFECT; SKIN INFECTION; SODIUM BLOOD LEVEL; SYMPTOM; SYSTOLIC DYSFUNCTION; SYSTOLIC HEART FAILURE; THORAX PAIN; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; FEMALE; FOLLOW-UP STUDIES; HEART DISEASES; HUMANS; HYPERKALEMIA; MALE; MIDDLE AGED; POLYSTYRENES; RENAL INSUFFICIENCY, CHRONIC; RENIN-ANGIOTENSIN SYSTEM; SECONDARY PREVENTION; TREATMENT OUTCOME;

EID: 84855693262     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.20987     Document Type: Review

References (28)

1. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992; 327: 669-677.
2. Flather MD, Yusuf S, Køber L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet. 2000; 355: 1575-1581. (Pubitemid 30240501)
3. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003; 362: 772-776. (Pubitemid 37093917)
4. Anderson JL, Adams CD, Antman EM, et al. 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;123:e426-e579.
5. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999; 341: 709-717. (Pubitemid 29407370)
6. Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011; 364: 11-21.
7. Jafar TH, Stark PC, Schmid CH, et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med. 2003; 139: 244-252.
8. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993; 329: 1456-1462. (Pubitemid 23335891)
9. Parving HH, Persson F, Lewis JB, et al. AVOID Study Investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008; 358: 2433-2446. (Pubitemid 351793017)
10. Schrier RW., Hyperkalemia: a threat to RAAS inhibition? Nat Rev Nephrol. 2010; 6: 245-246.
11. Weir MR, Rolfe M., Potassium homeostasis and renin-angiotensin- aldosterone system inhibitors. Clin J Am Soc Nephrol. 2010; 5: 531-548.
12. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004; 351: 543-551. (Pubitemid 39025171)
13. Lopes RJ, Lourenco AP, Mascarenhas J, et al. Safety of spironolactone use in ambulatory heart failure patients. Clin Cardiol. 2008; 31: 509-513.
14. Sterns RH, Rojas M, Bernstein P, et al. Ion-exchange resins for the treatment of hyperkalemia: are they safe and effective? J Am Soc Nephrol. 2010; 21: 733-735.
15. Watson M, Abbott KC, Yuan CM., Damned if you do, damned if you don't: potassium binding resins in hyperkalemia. Clin J Am Soc Nephrol. 2010; 5: 1723-1726.
16. Trottier V, Drolet S, Morcos MW., Ileocolic perforation secondary to sodium polystyrene sulfonate in sorbitol use: a case report. Can J Gastroenterol. 2009; 23: 689-690.
17. Bomback AS, Woosley JT, Kshirsagar AV., Colonic necrosis due to sodium polystyrene sulfate (Kayexalate). Am J Emerg Med. 2009; 27: 753. e1- e2.
18. Thomas A, James BR, Landsberg D., Colonic necrosis due to oral kayexalate in a critically-ill patient. Am J Med Sci. 2009; 337: 305-306.
19. US Food and Drug Administration. Kayexalate (sodium polystyrene sulfonate powder). Accessed April 11, 2011.
20. Levey AS, Coresh J, Greene T, et al. Chronic Kidney Disease Epidemiology Collaboration. Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem. 2007; 53: 766-772. (Pubitemid 46580250)
21. Levey AS, Coresh J, Balk E, et al. National Kidney Foundation. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003; 139: 137-147.
22. Mahadevan G, Davis RC, Frenneaux MP, et al. Left ventricular ejection fraction: are the revised cut-off points for defining systolic dysfunction sufficiently evidence based? Heart. 2008; 94: 426-428. (Pubitemid 351441395)
23. Tomino Y, Yamazaki T, Shou I, et al. Dose-response to a jelly preparation of calcium polystyrene sulfonate in patients with hyperkalemia-changes in serum potassium levels with or without a RAAS inhibitor. Clin Nephrol. 2007; 68: 379-385. (Pubitemid 350258766)
24. Chen CC, Chen CA, Chau T, et al. Hypokalaemia and hypomagnesaemia in an oedematous diabetic patient with advanced renal failure. Nephrol Dial Transplant. 2005; 20: 2271-2273. (Pubitemid 41510111)
25. Pitt B, Anker SD, Bushinsky DA, et al. for the PEARL-HF Investigators. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J. 2011; 32: 820-828.
26. Filippi L, Cecchi A, Dani C, et al. Hypernatraemia induced by sodium polystyrene sulphonate (Kayexalate) in two extremely low birth weight newborns. Paediatr Anaesth. 2004; 14: 271-275. (Pubitemid 38373066)
27. Fernandez PC, Kovnat PJ., Metabolic acidosis reversed by the combination of magnesium hydroxide and a cation-exchange resin. N Engl J Med. 1972; 286: 23-24.
28. van der Meer P, van Veldhuisen DJ., To bind or not to bind: potassium-lowering drugs in heart failure. Eur Heart J. 2011; 32: 791-792.